BiotechTube
Home/Pipeline/Biosimilar to Prolia® (denosumab)

Biosimilar to Prolia® (denosumab)

Osteoporosis

Approved/Under ReviewLaunched in EU, under review in USN/A

Key Facts

Indication
Osteoporosis
Phase
Approved/Under Review
Status
Launched in EU, under review in US
Company
Teva

About Teva

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical leader with a dual strategy of being a generics/biosimilars powerhouse and an innovative specialty medicines developer. Its mission, 'We are all in for better health,' is executed through a focus on neuroscience and immunology, leveraging strategic partnerships and a robust pipeline. The company is currently in the 'Acceleration Phase' of its 'Pivot to Growth' plan, aiming for consistent financial performance and pipeline execution, having delivered three consecutive years of growth as of 2025.

View full company profile

Therapeutic Areas

NeuroscienceImmunology

Other Osteoporosis Drugs

DrugCompanyPhase
TeriparatideEpygen BiotechNot Disclosed
AGA2118Angitia BiopharmaceuticalsPhase 2
Teriparatide (PTH 1-34) ProcessNumafermCommercial
Recombinant TeriparatideParas Biopharmaceuticals FinlandPre-clinical
Stoboclo®/Osenvelt®CelltrionMarketed
SHR-1222Jiangsu Hengrui MedicinePhase III
Biosimilar DenosumabRichter GedeonPhase III
Teriparatide InjectionAmphastar PharmaceuticalsMarketed